Cordyceps cicadae mycelium active substances, preparation method, pharmaceutical composition and application thereof

ABSTRACT

A method of preparing  Cordyceps cicadae  mycelium active substances for preventing and/or treating xerophthalmia is provided. The method comprises: (a)culturing a  Cordyceps cicadae  mycelium in a plate media at 15 to 35° C. for 5 to 14 days; (b)inoculating the mycelium of step(a) to a flask containing liquid media and culturing it at 15 to 35° C. with a pH of 2 to 8 for 3 days; (c)inoculating the mycelium of step(b) to a fermenter tank and culturing it at 15 to 35° C. with a pH of 2 to 8 for 3 days, so as to obtain a  Cordyceps cicadae  mycelium fermentation liquid; (d)freeze-drying and grating the fermentation liquid, so as to obtain a  Cordyceps cicadae  mycelium powder; (e)extracting the powder with solvent, so as to obtain a  Cordyceps cicadae  mycelium extract; and (f)drying the extract, so as to obtained the  Cordyceps cicadae  mycelium active substances.

BACKGROUND

1. Technical Field

The present invention relates the development of Cordyceps cicadae (C.cicadae) mycelium active substances, in particularly relates to theapplication for preventing and/or treating xerophthalmia induced byphysical or chemical injuries.

2. Description of Related Art

Dry Eye Syndrome (Xerophthalmia)

“Xerophthalmia” is a common disease in Ophthalmology (eye) clinic(10-15% adult). Xerophthalmia is mainly caused by a deficiency of tearsor abnormal tear composition. The general symptoms of xerophthalmiainclude eye dryness, fatigue, sleepiness, foreign body sensation,itching, burning and pain sensations, heavy eyelids, sticky secretions,photophobia, increased wind and external stimuli sensitivities,transient blurred vision, and excessive tearing. The severe symptoms ofxerophthalmia include red, swollen, congestion, horny eye, corneal ulcerand conjunctivitis, which might affect vision if left untreated. Thecauses of deficiency of tears are many: tired eyes, wear contact lensfor a long time, ocular inflammation, normal aging process, hormonalimbalances, autoimmune diseases, diabetes, etc. As xerophthalmia is amulti-faceted problem, it is also called as dry eye syndrome.

Composition and Function of Tears

There is a tear film on the normal ocular surface. Tear film covers thecornea and conjunctiva so as to protect and lubricate the eyes. The oldtear film and excess tears flow through nasolacrimal duct. Tear filmcomprises three layers:

Oil (Lipid) Layer:

This lipid layer produced by the meibomian glands of the eyelid is theoutermost layer of the tear film. Its main function is to increase thesurface tension of the tear film, retard evaporative tear loss andprovide lubrication between the lids and the ocular surface.

Water (Aqueous) Layer:

This layer produced by the lacrimal gland is the middle layer of thetear film and accounted for most of the tear film. The water layercontains nutrients, vitamins and antibiotics. Its main function is toprovide a clear and lubricated eye surface, supply oxygen to cornea andto wash away foreign bodies.

Mucin Layer:

This layer produced by the conjunctival goblet cells is the innermostlayer of the tear film. Its main function is to ensure that the tearfilm can adhere to the ocular surface, provide a hydrophilic layer onthe eye and allow for even distribution of the tear film.

Deficiency or uneven distribution for any of these three layers of thetear film could cause dry eye symptoms.

Xerophthalmia is a chronic disease that cannot be cured but the symptomscan be treated. The current treatment of xerophthalmia consists ofmedical and surgical therapies:

Medical Therapies of Xerophthalmia

1. Artificial tears: The function of artificial tears comprises wettingeyes, diluting inflammatory substances and reducing tear osmolarity, andtherefore is the most common treatment for patients with xerophthalmia.If patients are allergic to preservatives or use artificial tears at ahigh frequency (above 4 to 6 times a day), it is recommended forpatients to use preservative-free artificial tears to lubricate theeyes.

2. Autologous serum: The composition of serum proteins in tearsresembles that of whole serum. Serum is rich in growth factors, andtherefore can be used to treat patients with xerophthalmia as naturaltear substitutes. The frozen serum can be preserved for 3 to 6 months,so the patients do not need frequent blood draws.

3. Mucolytics (mucus dissolving agents): They are medicines used totreat respiratory diseases. Mucolytics can reduce tear secretiondecrease tear volume and lyse mucous plaques on the ocular surface.

4. Lacrisert: This medication is a solid artificial tear that is placedinto the deepest section of lower eyelid to treat dry eyes. It works bymaintaining lubrication and keeping the eye moist within 24 hrs. Thedisadvantage of lacrisert is that it is hard to install, and it mightslightly affect patients' vision.

5. Anti-inflammatory therapy: In addition to deficiency of tears, ocularinflammation is also an important cause of xerophthalmia. Thus, use oftopical steroids or Restasis (cyclosporine ophthalmic emulsion) isanother treatment method. Restasis was approved by the FDA in 2002 asthe only therapeutic treatment to increase tear production in patientswith chronic dry eyes.

6. Antibiotics: Oral antibiotics, particularly tetracycline ordoxycycline, are effective treatments for eyelid inflammation,especially for patients with rosacea. These patients treated with oralantibiotics should practice frequent eyelid hygiene and apply warmcompresses. Moreover, topical vitamin A creams is another treatmentoption. The cream can be used before sleep but its effect is stillcontroversial.

7. If patients have an autoimmune disease, they should also refer to arheumatologist for evaluation.

Surgical Therapies of Xerophthalmia

Surgical therapies are generally used for patients with severe dry eyesor when medical treatments have proven ineffective. Common surgicaltherapies are as follows:

1. Punctal plugs: This method blocks the lacrimal canaliculi to conservethe tears so that most of tears can stay on the ocular surface andstable the tear film. In general, the ophthalmologist will useabsorbable inserts to tamponade at first. If this operation can reducethe symptoms of xerophthalmia, a permanent plug will be considered. If apunctal plug is to be used, patients must pay attention to inflammationas it can cause ocular surface damages.

2. Tarsorrhaphy: Patients suffering from severe dry eye, corneal ulcers,or Bell's palsy may perform Tarsorrhaphy to help protect the eye untilthe underlying condition can be corrected.

Diagnosis of Xerophthalmia

Diagnosis of xerophthalmia should be performed by a qualified physician.The diagnosis method includes interviews, physical examination and/orstandardized tests such as Schirmer's test, corneal and conjunctivalstaining test, and fluorescein tear film break-up time test.

Cordyceps cicadae (C. cicadae)

Description and Distribution

Cordyceps cicadae, also known as to chan hua, chong hua, chan cao, huchan, chan jun, chan yong cao, jin chan hua, chan rong and can rong, isa division of Ascomycotina, order of Claricipiyales, family ofClavicipitaceae and genus of Cordyceps fungi. Cordyceps species areinsect-fungus complexes that strictly parasitize on the larva of Cicadaflammate, Platypleura kaempferi, Crytotympana pustulata, Platylomiapieli, and many more. C. cicadae, C. sobolifera and C. cicadicola arethe most common types of Cordyceps and are classified based on the hostsin which they reside. The genus is mainly distributed in subtropical andtropical region such as south Yangtze River, i.e. Fujian, Zhejiang,Sichuan, Yunnan and Jiangsu in China. The genus is also distributed insome mountains in Taiwan.

The sexual stage of Paecilomyces cicadae is called C. cicadae, alsoknown as du jiao long.

Potential Pharmacology of C. cicadae

C. cicadae have a long history of use in traditional medicine. InHerbology of classified syndromes documented by Shen-wei Tang in theNorthern Song Dynasty, it was written that C. cicadae is sweet inflavor, cold in nature and nontoxic, which can dispel wind and heat fromthe body, relieve convulsion and spasm. It is intended for morbid nightcrying of babies and palpitation (Compendium of Materia Medica).

C. cicadae had been used as a medicine for about 1,500 years in China,which was 800 years longer than C. sinensis. C. cicadae was introducedto central China from Tibet in Qing Dynasty, and was recorded in theancient scriptures of material medica as a chinese materia medica. Theterm of C. cicadae was first mentioned in the Process Analysis aboutTripterygium written by Xiao Lei in the Liu Song Period of Northern andSouthern Dynasties. In this book, it is recorded that C. cicadae withcontact white flower should be used, and coating mud should be removedbefore boiling overnight. The next day, it is dried and grinded intopowder.

It was recorded in classic medical work of Collections of the herbscompiled by Su song in the Song Dynasty that horn-like (or antler-like)protuberances occurred on the heads of Cicada in mountain, which iscalled C. cicadae. Compendium of Materia Medica said “The effectivenessof chán huā is similar to that of Cicada slough, which could curemalaria.” However, no one has yet produced such evidence.

Many tradition medicine products comprise of C. cicadae called “wan yingchan hua san”, “chan hua ming mu fang” and “chan hua wu wei san” havebeen documented in (Index of Chinese medicine) and (Zhōng huá yàoh{hacek over (a)}i).

A previous study has showed that among the patients subjected to therapyproject of combining “chan hua wu wei san” and western medicine, 14subjects of which achieved a normal intraocular pressure (>1.33 kPa),with a response rate of 46.67%. However, among 30 patients underwentwestern medicine treatment group, 8 patients achieved a normalintraocular pressure, with an average intraocular pressure of 0.41 kPaand a response rate of 26.67% (1994, Guang-hua Peng). Furthermore, theclinical trials conducted in 100 patients diagnosed with vernalconjunctivitis revealed that “wan ying chan hua san” could alleviateconjunctival congestion and reduce the incidence of relapse. Theresponse rates was 78% in the treatment group, whereas, only 26% in thecontrol group. The 1-year recurrence rate was 22% and 88%, respectively.

Both C. cicadae and C. sinensis are fungus-insect complexes with similarcomposition. Thus, C. cicadae is often viewed as a substitute of C.sinensis. As the wild C. sinensis resources are decreasing every year,artificial culture of C. cicadae received great attention as a promisingalternative for efficient production. Since the production of wild C.cicadae is particularly affected by climate or human factors, usingartificial cultured C. cicadae to replace the wild ones is therefore agood idea. Due to its high economic value, many researchers havecultivated the C. cicadae mycelium by liquid culture.

SUMMARY

The present invention provides Cordyceps cicadae (C. cicadae) myceliumactive substances, preparation method, and the application fortreating/preventing corneal injury or xerophthalmia induced by physicalor chemical damages. Compared to general treatments of xerophthalmia(medicine or eye drops), the present invention provides a much safer,easier way to prevent or treat this disease. The C. cicadae myceliumactive substances of present invention are natural and are safer thanother drugs.

According to one embodiment of the present invention, a method forpreparation a C. cicadae mycelium active substances is provided. The C.cicadae mycelium active substances are for preventing and/or treatingxerophthalmia. The method comprises the following steps:

(a) culturing a C. cicadae mycelium in a plate media at 15 to 35° C. for5 to 14 days;

(b) inoculating the C. cicadae mycelium of step(a) to a flask containingliquid media and culturing the mycelium at 15 to 35° C. with a pH of 2to 8 for few days;

(c) inoculating the C. cicadae mycelium of step(b) to a fermenter tankand culturing the mycelium at 15 to 35° C. with a pH of 2 to 8 for 3days, so as to obtain a C. cicadae mycelium fermentation liquid;

(d) freeze-drying and grating the C. cicadae mycelium fermentationliquid, so as to obtain a C. cicadae mycelium powder;

(e) extracting the C. cicadae mycelium powder with at least one solvent,so as to obtain C. cicadae mycelium extract; and

(f) drying the C. cicadae mycelium extract, so as to obtained the C.cicadae mycelium active substances.

In one embodiment of present invention, the culturing process of abovestep(b) is shake flask cultivation, and the flask is shaking at a speedrange between 10 and 250 rpm.

In one embodiment, the gas feed in the fermenter tank in step(c)comprises air, oxygen, carbon dioxide, helium or a combination thereof.

In one embodiment, the pressure of the fermenter tank in step(c) is at0.5 to 1.0 kg/cm², and the gas flow rate of fermenter tank is 0.01 to1.5 VVM.

In one embodiment, the liquid media used in step(b) and step(c) are thesame. The liquid media comprises grains, beans, inorganic salts,carbohydrates, yeast extract, malt extract or a combination thereof.

In one embodiment, the solvent of step(e) comprises water and alcohol.

In one embodiment, the extracting process of step(e) uses two solvents,which comprise water and alcohol.

In one embodiment, the alcohol of step(e) is methanol or ethanol.

In one embodiment of step(f), water extracts and alcohol extracts fromthe C. cicadae mycelium powder are mixed to obtain the C. cicadaemycelium active substances.

In one embodiment, the C. cicadae mycelium active substances comprisethe same weight of water extracts and alcohol extracts from the C.cicadae mycelium powder.

According to another embodiment of present invention, a C. cicadaemycelium active substances made by foregoing method is provided.

According to another embodiment of present invention, a method forpreventing and/or treating xerophthalmia is provided. The methodcomprises administrating to a subject an effective amount of theabove-mentioned C. cicadae mycelium active substances.

According to another embodiment of the present invention, apharmaceutical composition for preventing and/or treating xerophthalmiais provided. The pharmaceutical composition comprises a therapeuticallyeffective amount of above C. cicadae mycelium active substances inadmixture with a pharmaceutically acceptable carrier, excipient,diluents or adjuvant.

According to another embodiment of present invention, a method forpreventing and/or treating xerophthalmia is provided. The methodcomprises the pharmaceutical composition of claim.

Many of the attendant features and advantages of the present inventionwill becomes better understood with reference to the following detaileddescription considered in connection with the accompanying drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A to FIG. 1D show the test results of tear production in mice(corresponding with Table 3-1 to Table 3-4). FIG. 1A illustrates therelated tear change ratio of UVB mice; FIG. 1B illustrates the relatedtear change ratio of BAC mice; FIG. 1C illustrates the tear productionof UVB mice; FIG. 1D illustrates the tear production of BAC mice.

FIG. 2A and FIG. 2B show the test results of corneal smoothness in mice(corresponding with Table 4-1 and Table 4-2). FIG. 2A illustrates theaverage level of cornea smoothness of UVB mice; FIG. 2B illustrates theaverage level of cornea smoothness of BAC mice.

FIG. 3A and FIG. 3B shows the test results of corneal opacity in mice(corresponding with Table 5-1 and Table 5-2). FIG. 3A illustrates theaverage level of cornea opacity of UVB mice; FIG. 3B illustrates theaverage level of cornea opacity of BAC mice.

FIG. 4A and FIG. 4B show the test results of corneal topography in mice(corresponding with Table 6-1 and Table 6-2). FIG. 4A illustrates theaverage level of corneal topography of UVB mice; FIG. 4B illustrates theaverage level of corneal topography of BAC mice.

FIG. 5A and FIG. 5B show the test results of corneal staining in mice(corresponding with Table 7-1 and Table 7-2). FIG. 5A illustrates theaverage level of cornea staining of UVB mice; FIG. 5B illustrates theaverage level of cornea staining of BAC mice.

FIG. 6A and FIG. 6B show the test results of H-E stain in mice. FIG. 6Ais the corneal H-E stain of UVB mice; FIG. 6B is the corneal H-E stainof BAC mice.

FIG. 7A to FIG. 7D show the test results of tear film breakup time(TBUT) in mice (corresponding with Table 8-1 to Table 8-4). FIG. 7Aillustrates the tear film breakup time of UVB mice; FIG. 7B illustratesthe tear film breakup time of BAC mice; FIG. 7C illustrates the relativetear film breakup time of UVB mice; FIG. 7D illustrates the relativetear film breakup time of BAC mice.

FIG. 8A and FIG. 8B show the test results of corneal sensitivity test inmice (corresponding with Table 9-1 and Table 9-2). FIG. 8A illustratesthe average level of corneal sensitivity of UVB mice; FIG. 8Billustrates the average level of corneal sensitivity of BAC mice.

DETAILED DESCRIPTION Principles

The cornea is one the most sensitive tissue in human body, as it isdensely innervated with sensory nerve fibers. The cornea is located inthe front portion of eye, is in direct contact with the air, contains novascular tissue, obtains nutrients and oxygen from tears and aqueoushumor, and is easily infected. Embodiments of the present invention usea physical or chemical method to induce corneal injuries, and evaluatethe effects of Cordyceps cicadae mycelium active substances onpreventing and/or treating eye diseases caused by corneal injuries (suchas Xerophthalmia).

Ultraviolet (UV) can be divided into three types by wavelength: UVA(315-380 nm), UVB (280-315 nm) and UVC (100-280 nm). Excessive exposureto ultraviolet radiation (especially for UVB) can cause photochemicaldamage to the eye. UV may induce formation of free radicals, and thusinactivates the antioxidant enzyme activity in the cornea. UVB rays areabsorbed by the cornea, and can cause ocular surface disorders, cornealinjury, conjunctival connective tissue proliferation, keratinocytehyperplasia, and can accelerate the aging process of the eye and thetissue around the eye. Ongoing exposure to UVB can cause pain andforeign body sensation in the eye, corneal inflammation, epithelialdesquamated and degenerative cornea. Sunglasses are used to protect theeyes from the sun, but the public seldom think to protect their eyes.The public usually ignores the damage, resulting in decreased tearproduction and increased risk of xerophthalmia.

Benzalkonium chloride (BAC, BAK) is a cationic surfactant (non-oxidizingantiseptic) for sterilization, disinfection, antisepsis, emulsification,detergency, solubilization, etc. BAC was added in eye drops as apreservative, but recent research has shown that this compound may causetear film instability, loss of goblet cells, conjunctival squamousmetaplasia and apoptosis, corneal epithelium or eye tissues injury. Mildsymptoms of eye injury include inflammation and xerophthalmia, andsevere symptoms include permanent injury to the ocular surface and mightaffect vision. The reason why BAC causes above effects has not yet beenclarified, but current research confirmed that BAC induces release ofproinflammatory cytokine, apoptosis and oxidative stress, which can leadto dysregulated immune reactions and thereby cause chronic inflammatory.In addition, BAC can cause detrimental effect on the tear film stabilityand corneal surface integrity by direct interaction with the lipidbilayer.

Based on the above principles, the present invention designs two animalmodels (UVB and BAC mice) to observe the application of C. cicadaemycelium active substances on preventing and/or treating xerophthalmiainduced by physical or chemical damages.

Experimental Methods

Preparation of C. cicadae Mycelium Active Substances

Source of Cordyceps cicadae Mycelium

Cordyceps cicadae (C. cicadae) mycelium in embodiments of presentinvention is obtained by following steps: gathering a natural TaiwaneseC. cicadae strain, separating its mycelium and storing the subculture onthe plate media. The gene sequence of strain is confirmed as C. cicadaeby Taiwan Food Industry Research and Development Institute. This strainhas been deposited in public repository (Bioresource Collection andResearch Center, BCRC; China General Microbiological Culture CollectionCenter, CGMCC) and the Storage No. are MU30106 (BCRC) and 10486 (CGMCC).However, it is noted that the C. cicadae active substances of presentinvention are not limited to any particular species but widely includethose known in the art.

Liquid Culture

C. cicadae mycelium and C. cicadae mycelium active substances wasestablished by growing its mycelium on the plate media at 15 to 35° C.(preferably 25° C.) for 5 days to 2 weeks, and then the mycelium wasinoculated into a flask containing liquid media. The above mycelium iscultured in the flask at 15-35° C. (preferably 25° C.), pH 2-8(preferably pH 4-7, more preferably pH 4.5) and shake at a rate below10-250 rpm for about 3 days. The culture time may be adjusted dependingon the environment and growth of mycelium. Then the mycelium is furthertransferred to a fermenter tank (the media in the fermenter tank isshown in Table 1, and is the same liquid media used in the flask). Thecondition in the fermenter tank is set to a temperature of 15-35° C.(preferably 25° C.), a pressure of 0.5 -1.0 kg/cm², a pH of 2-8, astirring rate of 10-150 rpm (or air lift), and an air flow rate of0.01-1.5 VVM (air could be replace by air, oxygen, carbon dioxide,helium or combination thereof, preferably air) for 3 to 5 days to obtainC. cicadae mycelium fermentation liquid. The fermentation liquidcomprises mycelium, supernatant, and the C. cicadae mycelium activesubstances of the present invention. The C. cicadae myceliumfermentation liquid could also be dried to form powder.

TABLE 1 Recipe of media Ingredient Amount (weight %) Carbon and Nitrogensources 0.01~5 Proteins and their hydrolysates 0.01~2 Yeast or maltextract (powder, cream) 0.001~2  Inorganic salts  0.0001~0.05Carbohydrate  0.01~10

In the above ingredient, carbon and nitrogen sources may be cereals(grains) or legumes (such as soya bean, mung bean or Glycine max);inorganic salts may be magnesium sulfate, dipotassium phosphate,monopotassium phosphate, ferric sulfate, etc.; carbohydrate may beglucose, fructose, maltose, sucrose, etc. It is noted that the aboverecipe of the media is just an example. The actual recipe of media mayadjusted if necessity. Alternatively, the commercial media could beused.

Drying

The drying method may includes (but not limited to): spray drying, hotair drying, drum drying, freeze drying, concentration, etc. Thefermentation liquid is dried to form powder.

Extraction

1. Water Extraction

Dissolve the drying fermentation liquid powder in water and heat thesolution at 90 -121° C. for few minutes. After cooling, dry the solutionby one of the above drying methods (i.e. rotary evaporator) so as toobtain the water extract of the C. cicadae mycelium.

2. Alcohol Extraction

Dissolve the drying fermentation liquid powder in alcohol solvents(1-100 weight or volume percentage of methanol or ethanol), stir thesolution for few minutes, and dry the solution by one of the abovedrying method (i.e. rotary evaporator) so as to obtain alcohol extractof C. cicadae mycelium.

3. Extracts Mixture (in Any Proportion)

The water extract and the alcohol extract of C. cicadae mycelium couldbe mixed in any proportion, and the present invention is not limitedthereto.

EXAMPLE 1 Liquid culture and Preparation of C. cicadae Mycelium ActiveSubstances

Cordyceps cicadae Mycelium:

Grow C. cicadae mycelium on plate media (Potato Dextrose Agar, PDA) at25° C. for about 5 days.

Liquid Culture in a Flask:

Inoculate the mycelium from the plate to a flask containing media at pH4.5, and incubate on a shaker (120 rpm) at 25° C. for 3 days (the recipeof flask media is shown in Table 2).

TABLE 2 Recipe of flask media Ingredient Amount (weight %) Sucrose 2.0Yeast extract 0.5 Bean flour 1.0

Liquid Culture in a Fermenter Tank:

The liquid media of fermenter is similar to that of the flask media(Table 2). The flask culture was inoculated to a fermenter tank at apressure of 0.5 to 1.0 kg/cm², an air flow rate of 0.01 to 1.5 VVM,about 25° C., pH 4.5 and a stirring speed of 10-150 rpm or air lift for3 days. The obtained mycelium and supernatant are called fermentationliquid. The fermentation liquid includes the active substances of thepresent invention. Freeze-drying the fermentation liquid can obtain thepowder.

Preparation of Extracts:

Water Extraction

Dissolve the powder in 20 times volume of distilled water and heat thesolution at 100° C. for 30 minutes. After cooling, dry the solution byfreeze-drying so as to obtain water extract of C. cicadae mycelium.

Alcohol Extraction

Dissolve the powder in 20 times volume of ethanol and place the solutionin an ultrasonic bath for 30 minutes. The solution is then centrifugeand the supernatant is concentrated to obtain alcohol extract of C.cicadae mycelium.

The Extract Mixture

Mix the above mentioned water and alcohol extract of C. cicadae myceliumin the same weight, and then freeze-dry the mixture to obtain awater/alcohol extract mixture.

Results:

20 metric tons of C. cicadae mycelium fermentation liquid could be driedto about 110 kg freeze-dried powder. After extraction process, a higheryield of C. cicadae mycelium active substances is obtained forpreventing/treating xerophthalmia induced by physical or chemicaldamages. The C. cicadae mycelium active substances exist in thefermentation liquid (mycelium and supernatant), the freeze-dried powder,the water/alcohol extract mixture, etc. of the present embodiment. Thefollowing Example 2 uses water/alcohol extract mixture as C. cicadaemycelium active substances.

EXAMPLE 2 Xerophthalmia Animal Model and Analysis 1. Establishment of aMice Animal Model of Xerophthalmia

Experimental Animals:

Female mice at 7 to 10 weeks of age weighed 25 to 33 g (ICR strain) werepurchased from BioLASCO Taiwan and maintained in Chung Shan MedicalUniversity Laboratory Animal Center on a 12-h light/dark cycle inconstant temperature and humidity. Mice were given food and water adlibitum during the whole experiment.

(1) Xerophthalmia Induced by Physical Damages Using a UV Lamp (UVB)

A UV lamp is bought from Vilber lourmat (model: VL-6MC). The wavelengthis set to 280 nm˜320 nm, and the main peak is at 312 nm.

Before the test, the mice were randomly divided into four groups of six:a blank control group (fed saline without UVB radiation), a UVB group(fed saline with UVB radiation), a low-dose group (fed 10 mg/kg.bw C.cicadae mycelium active substances with UVB radiation) and a high-dosegroup (fed 100 mg/kg.bw C. cicadae mycelium active substances, with UVBradiation).

The entire experiment was carried out for 10 days. For 10 days, theexperimental groups (low-and high-dose groups) were fed with thepredetermined doses of C. cicadae mycelium active substances(water/alcohol extract mixture) daily. From the 4th day to the end ofthe experiment, the mice of the UVB and the experimental groups wereanesthetized with 2.5% Avertin, placed in a black box, and irradiatedwith 0.72 J/cm² UVB for 90 seconds to induce a dry eye condition.UVB-induced changes in tear production, tear film break-up time, cornealsensitivity, corneal surface damage parameters and tissue sections wereevaluated to determine the effectiveness of C. cicadae mycelium activesubstances for treating/preventing xerophthalmia. The data shows(described in details later) that the C. cicadae mycelium activesubstances are effective to xerophthalmia induced by UVB.

(2) Xerophthalmia Induced by Chemical Damages Using BAC

Before the test, the mice were randomly divided into four groups of six:a blank control group (fed saline without BAC treatment), BAC group (fedsaline with BAC treatment), a low-dose group (fed 10 mg/kg.bw C. cicadaemycelium active substances, with BAC treatment) and a high-dose group(fed 100 mg/kg.bw C. cicadae mycelium active substances, with BACtreatment)

The entire experiment was carried out for 14 days. For 14 days, theexperimental groups (low- and high-dose groups) were fed thepredetermined doses of C. cicadae mycelium active substances(water/alcohol extract mixture). From the 4th day to the end of theexperiment, 5 μl of 0.2% BAC was dropped on the eyes of the mice of theBAC and experimental groups to induce a dry eye condition. BAC-inducedchanges in tear production, tear film break-up time, cornealsensitivity, corneal surface damage parameters and tissue sections wereevaluated to determine the effectiveness of the C. cicadae myceliumactive substances for treating/preventing xerophthalmia. The data shows(described in details later) that the C. cicadae mycelium activesubstances is effective to xerophthalmia induced by BAC.

2. Assessments of Ocular Surface Damage for Xerophthalmia

This experiment uses two types of mice animal models (UVB and BAC) toobserve the effectiveness of the C. cicadae mycelium active substancesfor protecting/treating xerophthalmia. The ocular surface damage leveland assessment for xerophthalmia were measured during the experiment andat the end of experiment.

The assessments for xerophthalmia is similar to that of a clinicalxerophthalmia diagnosis, which includes a tear production test, acorneal surface damage test, a H&E staining test, a tear film breakuptime and a corneal sensitivity test. The corneal surface damage testincludes assessment for corneal smoothness, corneal opacity, cornealtopography and corneal staining.

(1) Tear Production Test

The tear production test measures the basic tear production. This testuses litmus paper strips to measure the production of tears. The paperstrip is inserted into the lower eyelid of mice eye for few seconds. Thepaper is then removed and the amount of moisture is measured.

(2) Corneal Surface Damage Analysis

The analysis includes assessments for corneal smoothness, cornealopacity, corneal topography and corneal staining. The higher the levelindicates a more severe damage to the cornea.

(2.1) Corneal smoothness was evaluated by the regularity of the ringlight reflected off the wet cornea. The result is grade to level 0-5:level 0 indicates the reflect light is annular without distortion; level1-3 indicate ¼, ½, and ¾ of ring portion are distorted, respectively;level 4 indicates the whole ring light is distorted; level 5 indicatesthe light is extremely distorted thus cannot be recognized as a ring.

(2.2) Corneal opacity was evaluated by lighting the eyes. The result isgraded to 4 levels by transparency. Level 1 indicates normal cornealtransparency; Level 1-3 indicate mild, moderate, moderate (with uncleariris) opaque degeneration; Level 4 indicates severe opaque degeneration,i.e. white turbidity and corneal ulceration.

(2.3) Corneal topography was evaluated by projecting quintuple ringgraph on the ocular surface. The assessment of corneal topography is todivide the ocular surface into four areas, each with 5 arc lines (fromthe projected quintuple rings). If any of the arc line is twisted orunreadable, score 1 point. A total of 20 points was scored on each eye.The higher the point, the lower the smoothness of cornea. The result isgraded to level 0-5. Level 1 is 0 point; Level .1 is 1-4 points; Level 2is 5-9 points; Level 3 is 10-14 points; Level 4 is 15-19 points andLevel 5 is 20 points.

(2.4) Corneal staining was evaluated by scoring fluorescein stainingunder a hand-held slit lamp. The size of stain is graded to level 0-5.Level 0 is without punctuate staining; Level 1 indicates 25% or lessarea with scattered punctuate staining; Level 2 indicates 25-50% areawith diffuse punctate staining; Level 3 indicates 50-75% area withdiffuse punctate staining; Level 4 indicates 75% -99% area with abundantpunctate staining, Level 5 indicates the entire cornea is stained.

(3) Hematoxylin and Eosin Stain (H & E Stain)

This is one of the most common histological staining methods. Hemalumcolors nuclei of cells while eosin colors cytoplasm and extracellularmatrix in red. After the end of experiment, the mice were sacrificed.The eye tissues of the mice were soaked in 3% formalin and dehydrated byn-butanol. The H&E test was performed to observe the cell layers,patterns and the thickness of central cornea, thereby evaluating theeffectiveness of the C. cicadae mycelium active substances.

(4) Tear Film Break-Up Time (TBUT)

Tear film quality is one of factors causing xerophthalmia. A tear filmbreak-up time indicates the stability of the tear film and can be usedto evaluate the quality of the tear. 1 of 0.1% sodium fluoresceinsolution was dropped on the bulbar conjunctiva of the mice and the tearfilm break-up time was recorded after three blinks. 90 seconds later,the extent of cornea injury was evaluated by a microscope. The cornea isdivided into four quadrants (each quadrant has 4 points) and isindividually scored. 0 point indicates unstained; 1 point indicatesslightly stained but less than 30 dots; 2 points indicate more than 30staining dots but no diffusion; 3 points indicate severe staining anddiffusion in the quadrant, but no significant plaques; 4 point indicatesobvious fluorescent plaques.

(5) Corneal Sensitivity (CS)

This test uses Cochet and Bonnet aesthesiometer to measure the length offilament required to elicit a blink reflex. If mice have no blinkingresponse, retract the filament until the mice blink. Four times with noblinking response can be recorded as “no response”. In the absence ofblink response, the filament length was reduced by 0.5 cm and the animalretested. The filament ranges from 6 cm to 0.5 cm (0.5 cm interval) andcontacts the corneal surface in a perpendicular direction. The stimuluspressure applied is inversely proportional to the filament length. Blinkwith 0.5 cm filament contacts scores 0 point. Each test must beperformed by the same operator.

The above results are analyzed with Mann-Whitney U test by SPSS (18thversion). The asterisk (*) indicates a significant result with p<0.05.

EXAMPLE 3 Assessment for Effectiveness of the C. cicadae Mycelium ActiveSubstances for Preventing Xerophthalmia

1. Tear Production Test

In this test, the litmus paper with lmm width (Toyo Roshi Kaisha, Ltd)was inserted into the lower eyelid of the mouse's eye. 20 seconds later,the paper is removed and the amount of moisture is measured. The resultis shown in Table. 3-1 to Table 3-4 (corresponding to FIG. 1A to 1D).The result showed that C. cicadae mycelium active substances canincrease the tear production and reduce the relative tear change ratio,thus is good for preventing xerophthalmia.

TABLE 3-1 The related tear change ratio (mm) of UVB mice (Correspondingwith FIG. 1A) Group Day 4 Day 7 Day 10 Blank 0.00 0.04 0.09 UVB 0.000.06 0.21  10 mg/kg · bw 0.00 0.03 0.04 100 mg/kg · bw 0.00 0.06 0.08

TABLE 3-2 The related tear change ratio (mm) of BAC mice (Correspondingwith FIG. 1B) Group Day 4 Day 7 Day 10 Day 13 Blank 0.00 −0.04 −0.07−0.10 BAC 0.00 −0.22 −0.31 −0.04  10 mg/kg · bw 0.00 −0.25 −0.19 −0.03100 mg/kg · bw 0.00 0.02 0.06 0.06

TABLE 3-3 The tear production (mm) of UVB mice (Corresponding with FIG.1C) Group Day 4 Day 7 Day 10 Blank 2.00 2.06 2.17 UVB 1.89 1.97 2.25  10mg/kg · bw 2.00 2.06 2.08 100 mg/kg · bw 2.06 2.17 2.22

TABLE 3-4 The tear production (mm) of BAC mice (Corresponding with FIG.1D) Group Day 4 Day 7 Day 10 Day 13 Blank 2.31 2.17 2.03 2.03 BAC 2.221.72 1.56 2.11 10 mg/kg · bw 2.42 1.78 1.92 2.28 100 mg/kg · bw 2.142.11 2.17 2.17

2. Corneal Surface Damage Analysis

(1) Corneal smoothness was evaluated by the regularity of the ring lightreflected off the wet cornea. The integrity is grade to level 0 (withoutdistort) to 5 (severe distort). The results are shown in Table 4-1 andTable 4-2 (corresponding to FIG. 2A to 2B). The result shows the mice ofexperimental groups (feeding the C. cicadae mycelium active substances)have lower image distortion than those of the blank control group. Thusit is good for preventing Xerophthalmia.

TABLE 4-1 Average level of cornea smoothness of UVB mice (Correspondingwith FIG. 2A) Group 10 mg/kg · Mouse Blank UVB bw 100 mg/kg · bw 1 2.04.0 1.0 2.0 2 2.0 4.0 2.0 3.0 3 0.0 4.0 4.0 3.0 4 0.0 4.0 2.0 2.0 5 0.02.0 4.0 1.0 6 1.0 4.0 2.0 2.0 Avg. Level 0.8 3.7 2.5 2.2

TABLE 4-2 Average level of cornea smoothness of BAC mice (Correspondingwith FIG. 2B) Group 10 mg/kg · Mouse Blank BAC bw 100 mg/kg · bw 1 2.02.0 4.0 1.0 2 1.0 3.0 3.0 1.0 3 1.0 2.0 1.0 2.0 4 0.0 3.0 2.0 1.0 5 2.02.0 2.0 1.0 6 0.0 2.0 1.0 0.0 Avg. Level 1.0 2.3 2.2 1.0

(2) Corneal opacity was evaluated by lighting the eyes. The opacity isgraded to 4 levels by transparency. The result is shown in Table 5-1 and5-2 (corresponding with FIG. 3A and FIG. 3B).The result shows that inboth BAC and UVB tests, the mice of experimental groups (feeding the C.cicadae mycelium active substances) have lower corneal opacity levelthan those of the blank control group, and the corneal opacity of miceare improve by the C. cicadae mycelium active substances. Thus it isgood for preventing xerophthalmia.

TABLE 5-1 Average level of cornea opacity of UVB mice (Correspondingwith FIG. 3A) Group 10 mg/kg · Mouse Blank UVB bw 100 mg/kg · bw 1 0.50.5 1.0 1.0 2 0.5 1.0 0.5 0.0 3 0.0 1.0 0.5 0.5 4 0.0 1.0 0.0 1.0 5 0.00.5 0.5 0.0 6 0.5 1.0 0.0 0.0 Avg. Level 0.3 0.8 0.4 0.4

TABLE 5-2 Average level of cornea opacity of BAC mice (Correspondingwith FIG. 3B) Group 10 mg/kg · Mouse Blank BAC bw 100 mg/kg · bw 1 0.01.0 2.0 0.5 2 0.0 1.0 1.0 0.0 3 0.5 1.0 1.0 1.0 4 0.5 0.5 0.5 0.0 5 0.01.0 0.5 1.0 6 1.0 0.5 0.0 0.0 Avg. Level 0.3 0.8 0.8 0.4

(3) Corneal topography was evaluated by projecting quintuple ring graphon the ocular surface. The assessment of corneal topography is dividedthe ocular surface into four areas, each area includes 5 arc lines (fromthe projected quintuple rings). If any of the arc line is twisted orunreadable, score 1 point. All eye score 20 points. The result is gradedto level 0-5 and is shown in Table 6-1 and 6-2 (corresponding with FIG.4A and FIG. 4B). The result shows that in both BAC and UVB tests, themice of experimental groups (feeding the C. cicadae mycelium activesubstances) have lower ring distortion than those of the blank controlgroup, and the corneal smoothness of mice are improve by the C. cicadaemycelium active substances. Thus it is good for preventingxerophthalmia.

TABLE 6-1 Average level of corneal topography of UVB mice (Correspondingwith FIG. 4A) Group 10 mg/kg · Mouse Blank UVB bw 100 mg/kg · bw 1 4.03.0 1.0 3.0 2 2.0 2.0 2.0 3.0 3 0.0 2.0 1.0 2.0 4 0.0 4.0 2.0 1.0 5 0.02.0 3.0 1.0 6 1.0 2.0 3.0 1.0 Avg. Level 1.2 2.5 2.0 1.8

TABLE 6-2 Average level of corneal topography of BAC mice (Correspondingwith FIG. 4B) Group 10 mg/kg · Mouse Blank BAC bw 100 mg/kg · bw 1 2.03.0 4.0 0.0 2 0.0 1.0 2.0 1.0 3 0.0 1.0 1.0 1.0 4 1.0 3.0 1.0 0.0 5 1.01.0 1.0 0.0 6 1.0 2.0 1.0 0.0 Avg. Level 0.8 1.8 1.7 0.3

(4) Corneal staining was evaluated by scoring fluorescein staining undera hand-held slit lamp. The size of stain is graded to level 0-5. Theresult is shown in Table 7-1 to 7-2(corresponding to FIG. 5A to FIG.5D). The result shows that in both BAC and UVB tests, the mice ofexperimental groups (feeding the C. cicadae active substances) havelower staining area than those of the blank control group, thus is goodfor preventing xerophthalmia.

TABLE 7-1 Average level of corneal staining of UVB mice (Correspondingwith FIG. 5A) Group 10 mg/kg · Mouse Blank UVB bw 100 mg/kg · bw 1 2.03.0 1.0 1.0 2 2.0 2.0 1.0 2.0 3 1.0 2.0 2.0 1.0 4 1.0 3.0 2.0 1.0 5 0.02.0 3.0 0.0 6 0.0 3.0 2.0 2.0 Avg. Level 1.0 2.5 1.8 1.2

TABLE 7-2 Average level of corneal staining of BAC mice (Correspondingwith FIG. 5B) Group 10 mg/kg · Mouse Blank BAC bw 100 mg/kg · bw 1 1.02.0 3.0 1.0 2 0.0 2.0 2.0 1.0 3 1.0 2.0 2.0 1.0 4 2.0 3.0 1.0 1.0 5 1.03.0 2.0 0.0 6 1.0 4.0 1.0 1.0 Avg. Level 1.0 2.7 1.8 0.8

3. The corneal sections were stained with hematoxylin and eosin (HE).The result is shown in FIG. 6A and FIG. 6B. The result shows that inboth BAC and UVB tests, the mice of experimental groups (feeding the C.cicadae mycelium active substances) have higher and thicker cell layersthan those of the blank control group. Thus, it is good for preventingxerophthalmia.

4. The tear film break up time is a test to measure the relativestability of the precorneal tear film. The result is shown in Tables 8-1to 8-4 (corresponding with FIGS. 7A to 7D). The result shows that inboth BAC and UVB tests, the mice of experimental groups (feeding the C.cicadae active substances) have higher TBUT and relative TBUT than thoseof the blank control group. Thus, it is good for preventingxerophthalmia.

TABLE 8-1 Tear film breakup time (sec.) of UVB mice (Corresponding withFIG. 7A) Group Day 4 Day 7 Day 10 Blank 4.13 4.24 4.08 UVB 2.44 0.190.00 10 mg/kg · bw 2.83 1.56 0.35 100 mg/kg · bw 2.83 1.08 0.41

TABLE 8-2 Tear film breakup time (sec.) of BAC mice (Corresponding withFIG. 7B) Group Day 4 Day 7 Day 10 Day 13 Blank 6.50 3.67 4.17 3.00 BAC4.67 2.67 1.58 0.10 10 mg/kg · bw 4.00 3.83 3.00 2.42 100 mg/kg · bw4.00 4.33 3.50 4.0

TABLE 8-3 Relative tear film breakup time (sec.) of UVB mice(Corresponding with FIG. 7C) Group Day 4 Day 7 Day 10 Blank 0.00 0.03−0.01 UVB 0.00 −0.92 −1.00 10 mg/kg · bw 0.00 −0.45 −0.88 100 mg/kg · bw0.00 −0.62 −0.86

TABLE 8-4 Relative tear film breakup time (sec.) of BAC mice(Corresponding with FIG. 7D) Group Day 4 Day 7 Day 10 Day 13 Blank 0.00−0.44 −0.36 −0.54 BAC 0.00 −0.43 −0.66 −0.98 10 mg/kg · bw 0.00 −0.04−0.25 −0.40 100 mg/kg · bw 0.00 0.08 −0.13 0.00

5. Corneal sensitivity uses Cochet and Bonnet aesthesiometer to measurethe corneal sensitivity. The result is shown in Table 9-1 and 9-2(corresponding with FIG. 8A and FIG. 8B).The result shows that in bothBAC and UVB tests, the mice of experimental groups (feeding C. cicadaemycelium active substances) have lower corneal sensitivity than those ofthe blank control group. Thus, it is good for preventing xerophthalmia.

TABLE 9-1 Average level of corneal sensitivity (mm) of UVB mice(Corresponding with FIG. 8A) Group Day 4 Day 7 Day 10 Blank 0.0003750.000500 0.000250 UVB 0.000500 0.001875 0.002125 10 mg/kg · bw 0.0003750.000500 0.001250 100 mg/kg · bw 0.001125 0.000375 0.000375

TABLE 9-2 Average level of corneal sensitivity (mm) of BAC mice(Corresponding with FIG. 8B) Group Day 4 Day 7 Day 10 Day 13 Blank0.006667 0.017778 0.000000 0.000000 BAC 0.000444 0.037778 0.0700000.028333 10 mg/kg · bw 0.012222 0.021111 0.031667 0.025000 100 mg/kg ·bw 0.006667 0.013333 0.063333 0.000000

Example 3 proves that the C. cicadae mycelium active substances madefrom the above example is effective for treating xerophthalmia inducedby physical or chemical damages. Thus, the C. cicadae mycelium activesubstances of the present invention could be used for eye care,treatment and prevention for xerophthalmia.

It will be apparent to those skilled in the art that variousmodifications and variations can be made to the disclosed embodiments.It is intended that the specification and examples be considered asexemplary only, with a true scope of the disclosure being indicated bythe following claims and their equivalents.

What is claimed is:
 1. A method of preparing Cordyceps cicadae myceliumactive substances for preventing and/or treating xerophthalmia, whereinthe method comprises following steps: (a) culturing a Cordyceps cicadaemycelium in a plate media at 15 to 35° C. for 5 to 14 days; (b)inoculating the Cordyceps cicadae mycelium of step(a) to a flaskcontaining liquid media and culturing the mycelium at 15 to 35° C. witha pH of 2 to 8 for 3 days; (c) inoculating the Cordyceps cicadaemycelium of step(b) to a fermenter tank and culturing the mycelium at 15to 35° C. with a pH of 2 to 8 for 3 days, so as to obtain a Cordycepscicadae mycelium fermentation liquid; (d) freeze-drying and grating theCordyceps cicadae mycelium fermentation liquid, so as to obtain aCordyceps cicadae mycelium powder; (e) extracting the Cordyceps cicadaemycelium powder with at least one solvent, so as to obtain at least oneCordyceps cicadae mycelium extract; and (f) drying the Cordyceps cicadaemycelium extract, so as to obtained the Cordyceps cicadae myceliumactive substances.
 2. The method of claim 1, wherein the culturingprocess of step(b) is shake flask cultivation, and the flask is shakingat a speed range between10 and 250 rpm.
 3. The method of claim 1,wherein in step(c), the gas feed in the fermenter tank comprises air,oxygen, carbon dioxide, helium or a combination thereof.
 4. The methodof claim 1, wherein in step(c), the pressure of the fermenter tank is at0.5 to 1.0 kg/cm², and the gas flow rate of fermenter tank is 0.01 to1.5 VVM.
 5. The method of claim 1, wherein the liquid media used instep(b) and step(c) are the same, and the liquid media comprises grains,beans, inorganic salts, carbohydrates, yeast extract, malt extract or acombination thereof.
 6. The method of claim 1, wherein the solvent ofstep(e) comprises water and alcohol.
 7. The method of claim 1, whereinthe extracting process of step(e) uses two solvents, which comprisewater and alcohol.
 8. The method of claim 7, wherein the alcohol ismethanol or ethanol.
 9. The method of claim 8, wherein in step(f), waterextracts and alcohol extracts from the Cordyceps cicadae mycelium powderare mixed to obtain the Cordyceps cicadae mycelium active substances.10. The method of claim 8, wherein the Cordyceps cicadae mycelium activesubstances comprise the same weight of water extracts and alcoholextracts from the Cordyceps cicadae mycelium powder.
 11. A method ofpreparing a Cordyceps cicadae mycelium active substance for preventingand/or treating xerophthalmia, wherein the method comprises followingsteps: (a) culturing a Cordyceps cicadae mycelium in a plate media at 15to 35° C. for 5 to 14 days; (b) inoculating the Cordyceps cicadaemycelium of step(a) to a flask containing liquid media and culturing themycelium at 15 to 35° C. with a pH of 2 to 8 for 3 days; and (c)inoculating the Cordyceps cicadae mycelium of step(b) to a fermentertank and culturing the mycelium at 15 to 35° C. with a pH of 2 to 8 for3 days, so as to obtain a Cordyceps cicadae mycelium fermentation liquidcomprising the Cordyceps cicadae mycelium active substances.
 12. Themethod of claim 11, wherein the culturing method of step(b) is shakeflask cultivation, and the flask is shaking at a speed range between 10and 250 rpm.
 13. The method of claim 11, wherein in step(c), the gasfeed in the fermenter tank comprises air, oxygen, carbon dioxide, heliumor a combination thereof.
 14. The method of claim 11, wherein instep(c), the pressure of the fermenter tank is at 0.5 to 1.0 kg/cm², andthe gas flow rate of fermenter tank is 0.01 to 1.5 VVM.
 15. The methodof claim 11, wherein the liquid media used in step(b) and step(c) arethe same, and the liquid media comprises grains, beans, inorganic salts,carbohydrates, yeast extract, malt extract or a combination thereof. 16.A Cordyceps cicadae mycelium active substances for preventing and/ortreating xerophthalmia, which is prepared by the method of claim
 1. 17.A method for preventing and/or treating xerophthalmia, which comprisesadministrating to a subject an effective amount of the Cordyceps cicadaemycelium active substances of claim
 16. 18. A pharmaceutical compositionfor preventing and/or treating xerophthalmia, which comprises atherapeutically effective amount of the Cordyceps cicadae myceliumactive substances of claim 1 and a pharmaceutically acceptable carrier,excipient, diluents or adjuvant.
 19. A method for preventing and/ortreating xerophthalmia, which comprises administrating to a subject aneffective amount of the pharmaceutical composition of claim 18.